How fast does bone loss happen around menopause?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
Bone loss accelerates sharply around the final period. The Endocrine Society states that up to 20 percent of bone loss can occur across the menopause transition, and NIAMS notes the process often begins a year or two before menopause. The USPSTF recommends bone density screening for all women aged 65 and older, and earlier for those at increased risk.
Bone loss around menopause is fast and front loaded. The Endocrine Society states that up to 20 percent of bone loss can occur across the menopause transition, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases notes that for many women the disease begins to develop a year or two before menopause. Estrogen restrains the cells that break bone down, so when estrogen falls, breakdown outpaces formation for several years.
Why the timing matters
The window of rapid loss is narrow and it is not symptomatic. Bone does not ache while it thins. Most women learn about it after a wrist or vertebral fracture, or on a scan ordered for another reason. Because the loss clusters around the final menstrual period, the years when prevention is most useful are the same years when women are usually most preoccupied with hot flashes and sleep. NIAMS identifies osteoporosis as the major cause of fractures in postmenopausal women.
When to be scanned
The US Preventive Services Task Force recommendation, updated in January 2025, is a grade B recommendation to screen for osteoporosis with bone density testing in all women aged 65 and older, and in postmenopausal women younger than 65 who are at increased fracture risk as estimated by a formal clinical risk assessment. FRAX estimates 10 year probability of hip fracture and major osteoporotic fracture for people aged 40 to 90 and is the tool most often used to decide about earlier scanning.
What actually protects bone
| Intervention | What it does |
|---|---|
| Systemic estrogen therapy | FDA approved for prevention of postmenopausal osteoporosis; reduced hip fracture in both WHI arms |
| Resistance and impact exercise | Loads bone and maintains the muscle that protects against falls |
| Adequate calcium and vitamin D | Supports bone formation, recommended by the Endocrine Society |
| Bisphosphonates, denosumab, anabolic agents | Used when osteoporosis is established or fracture risk is high |
| Stopping smoking, limiting alcohol | Removes two modifiable accelerators of bone loss |
If you are approaching or just past your final period, ask whether a baseline bone density scan is reasonable for you rather than waiting until 65, particularly if you had early menopause, a parent with a hip fracture, low body weight, long term steroid use, or a previous fracture after age 50. If you are already on hormone therapy for symptoms, bone protection comes with it, and that should be part of the decision about when to stop.
The clinical detail
The USPSTF 2025 statement gives a grade B recommendation for DXA screening in women 65 and older, and in postmenopausal women under 65 at increased risk identified by clinical risk assessment tools including FRAX, ORAI, OST and the Garvan calculator. In the WHI intervention phase, hip fracture fell by 6 events per 10,000 women per year with estrogen plus progestin and by 7 with estrogen alone, hazard ratios 0.67 in both arms. Estrogen product labels carry prevention of postmenopausal osteoporosis as an approved indication. Bone density is only one input: prior fragility fracture, glucocorticoid exposure, early menopause and parental hip fracture all shift risk independently of the T-score.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- Menopause and Bone Loss. Endocrine Society
- Osteoporosis. National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH
- Osteoporosis to Prevent Fractures: Screening. U.S. Preventive Services Task Force
- Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the WHI Randomized Trials. JAMA. PMID 24084921
- Estradiol Transdermal System, full prescribing information. DailyMed, U.S. National Library of Medicine
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.